Alx Oncology Holdings Inc (ALXO) Stock Price, Quote & News

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 466 7125

Website: www.alxoncology.com

Address:

323 Allerton Avenue, South San Francisco, United States

BiopharmaWatch_com Jun. 16 at 6:14 PM

🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting

0 · Reply

Andrebrx1 Jun. 11 at 4:18 PM

$ALXO catalyst soon

0 · Reply

P119 Jun. 4 at 1:17 AM

$ALXO moving to 2$ or squeeze upper?

0 · Reply

Arthur_PL May. 30 at 9:35 PM

$ALXO it's interesting reading https://finance.yahoo.com/quote/ALXO/community/

0 · Reply

MakingMoneeeeyHeeere May. 30 at 9:39 AM

$ALXO what the fc is going on

0 · Reply

PlaceboSlayerMDPhD May. 22 at 8:14 PM

$ALXO The lesson here is If a drug class fails in biological mechanism time and time again You might be clowning yourself to think it would be different this time No amount of increased safety will change that

2 · Reply

MakingMoneeeeyHeeere May. 22 at 6:26 PM

$ALXO The CEO is POS.

0 · Reply

theBigDollarski May. 22 at 4:27 PM

$ALXO Tang has a stake now...wonder if he's going to put a lowball offer in now

1 · Reply

Thestocktraderhubzee May. 20 at 12:12 PM

$ALXO ALX Oncology Unveils Clinical Development Plans For ALX2004, A ADC Targeting EGFR-Expressing Tumors, With Phase 1 Trials Set For Mid-2025 Following FDA IND Clearance And Initial Data Expected In 1H 2026, While Advancing CD47-Blocker Evorpacept In Breast And Colorectal Cancer Trials Also Starting Mid-2025

0 · Reply

MakingMoneeeeyHeeere May. 20 at 5:21 AM

$ALXO The only consolation is that the new drug was developed under the direction of Alan Sandler.

0 · Reply

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 4 weeks ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 13, 2025, 8:00 AM EDT - 5 weeks ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 8, 2025, 8:30 AM EDT - 5 weeks ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 2, 2025, 8:00 AM EDT - 6 weeks ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 25, 2025, 1:10 PM EDT - 7 weeks ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 9:00 AM EDT - 7 weeks ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Mar 6, 2025, 4:01 PM EST - 3 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 8:00 AM EST - 3 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Feb 27, 2025, 8:00 AM EST - 3 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 18, 2025, 8:00 AM EST - 4 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Jan 23, 2025, 8:00 AM EST - 5 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 22, 2025, 4:01 PM EST - 5 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 21, 2025, 5:00 PM EST - 5 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Dec 18, 2024, 8:00 AM EST - 6 months ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Nov 14, 2024, 8:00 AM EST - 7 months ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 7, 2024, 4:00 PM EST - 7 months ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 1, 2024, 5:30 PM EDT - 8 months ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Sep 11, 2024, 10:36 PM EDT - 9 months ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Aug 6, 2024, 4:01 PM EDT - 11 months ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Jul 31, 2024, 4:01 PM EDT - 11 months ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 11 months ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

$ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)$

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Mar 7, 2024, 4:03 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Dec 8, 2023, 8:30 AM EST - 1 year ago

ALX Oncology shares jump 9% after Jefferies upgrade

Nov 13, 2023, 4:05 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 10, 2023, 4:05 PM EDT - 1 year ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 9, 2023, 12:38 AM EDT - 1 year ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 5, 2023, 8:00 AM EDT - 1 year ago

ALX Oncology Announces Pricing of Public Offering

Oct 4, 2023, 4:10 PM EDT - 1 year ago

ALX Oncology Announces Proposed Public Offering

Oct 3, 2023, 6:00 AM EDT - 1 year ago

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 2, 2023, 4:05 PM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Sep 6, 2023, 8:00 AM EDT - 1 year ago

ALX Oncology Realigns Executive Leadership Team

Aug 31, 2023, 7:00 AM EDT - 1 year ago

ALX Oncology Announces September Investor Conference Participation

Aug 10, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Jun 26, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

May 11, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 9, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

Mar 14, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

Mar 13, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

Mar 9, 2023, 4:01 PM EST - 2 years ago

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

Feb 16, 2023, 7:00 AM EST - 2 years ago

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

Jan 5, 2023, 7:00 AM EST - 2 years ago

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

BiopharmaWatch_com Jun. 16 at 6:14 PM

0 · Reply

Andrebrx1 Jun. 11 at 4:18 PM

$ALXO catalyst soon

0 · Reply

P119 Jun. 4 at 1:17 AM

$ALXO moving to 2$ or squeeze upper?

0 · Reply

Arthur_PL May. 30 at 9:35 PM

$ALXO it's interesting reading https://finance.yahoo.com/quote/ALXO/community/

0 · Reply

MakingMoneeeeyHeeere May. 30 at 9:39 AM

$ALXO what the fc is going on

0 · Reply

PlaceboSlayerMDPhD May. 22 at 8:14 PM

2 · Reply

MakingMoneeeeyHeeere May. 22 at 6:26 PM

$ALXO The CEO is POS.

0 · Reply

theBigDollarski May. 22 at 4:27 PM

$ALXO Tang has a stake now...wonder if he's going to put a lowball offer in now

1 · Reply

Thestocktraderhubzee May. 20 at 12:12 PM

0 · Reply

MakingMoneeeeyHeeere May. 20 at 5:21 AM

$ALXO The only consolation is that the new drug was developed under the direction of Alan Sandler.

0 · Reply

DrGonzo69 May. 12 at 1:49 PM

$ALXO are we ever going to see $1 again???

0 · Reply

CAN_2409 May. 9 at 6:09 PM

$ALXO >>> CADL

0 · Reply

Golibajje May. 9 at 4:47 PM

$ALXO There is nothing to look forward other than bankruptcy! Jason and Pons are a bunch of crooks who got tons of money at the time when there is CD47 hype! Insiders continuously sold shares over the years knowing that Evorpacept wouldn’t work and not revealing the material facts! Over $500 millions to date has been spent.. largely on their salaries and bonuses! Now jumping on ADC, which has milestone payment tied to it.. guess for whom? Pons and his gang. This asset was acquired with milestone payments when Pons has conflicting interest in both companies! I hope someone files lawsuit and throw Jason and pons to prison!

2 · Reply

theBigDollarski May. 9 at 4:14 PM

$ALXO apparently this is priced for management to run it into the iceberg before they give themselves a good severance package

0 · Reply

JarvisFlow May. 9 at 11:30 AM

HC Wainwright & Co. updates rating for ALX Oncology Holdings ( $ALXO ) to Buy, target set at 5 → 2.

0 · Reply

topmik May. 9 at 7:59 AM

$ALXO

0 · Reply

theBigDollarski May. 8 at 4:04 PM

$ALXO looks like evorpacept is a flop....failed 4 trials

1 · Reply

MakingMoneeeeyHeeere May. 8 at 2:41 PM

$ALXO It takes a lot of hard work and perseverance to take a company from $16 to 30 cents. Incredible success!

0 · Reply

WAYWARD_SUN May. 8 at 2:36 PM

$ALXO

0 · Reply

Gabriel_DS May. 8 at 12:34 PM

$ALXO

2 · Reply

TheEdge13F May. 2 at 6:43 PM

$ALXO

0 · Reply

PenkeTrading May. 1 at 10:33 AM

I found you a Bullish Engulfing Candle Pattern on the daily chart of Alx Oncology Holdings . $ALXO #BullishEngulfingCandle #NASDAQ

1 · Reply

Market Cap	28.39M
Revenue (ttm)	0.00
Net Income (ttm)	-134.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	297,500
Avg Vol	479,562
Day's Range	N/A - N/A
Shares Out	53.40M
Stochastic %K	13%
Beta	1.16
Analysts	Strong Sell
Price Target	$2.25